ArticleCancer treatment and research communications2022

Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.

Steven H Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.